In June 2025, the Center for Drug Evaluation (CDE) of NMPA accepted two supplementary applications (CYHB2550240, CYHB2550241) for our Amoxicillin and Clavulanate Potassium for Suspension, further advancing the oral portfolio.
NEWS
CDE accepts two supplementary applications for Amoxicillin and Clavulanate Potassium for Suspension
2025-06-27 · Company News